Department of Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Pathol Int. 2012 Jul;62(7):471-6. doi: 10.1111/j.1440-1827.2012.02825.x. Epub 2012 May 9.
Ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) has been reported to show cancer-specific expression in early invasive lung adenocarcinoma. OCIAD2 shows high homology with OCIAD1, which was originally immunoscreened from ascites of a patient with ovarian cancer and found to be a tumor-specific protein. Therefore, like OCIAD1, OCIAD2 is expected to show high immunoreactivity in ovarian tumors. In this study, we examined the expression pattern of OCIAD2 in 117 ovarian mucinous tumors, and confirmed that it was more highly expressed in borderline tumor and carcinoma (51/74 cases, 69%) than in adenoma (6/43 cases, 14%). The immunoreactivity of OCIAD2 in borderline tumor and carcinoma was more specific than that of OCIAD1 (adenoma, 21/43 cases, 49%), and more sensitive than that of CEA (borderline tumor and carcinoma, 35/74 cases, 47%). Like OCIAD1, OCIAD2 is a cancer-related protein and its expression level increases during the course of malignant progression and is thought to be a very useful marker for evaluating the malignancy of ovarian mucinous tumors.
卵巢癌免疫反应性抗原结构域包含 2（OCIAD2）已被报道在早期浸润性肺腺癌中表现出肿瘤特异性表达。OCIAD2 与 OCIAD1 具有高度同源性，OCIAD1 最初是从卵巢癌患者的腹水中免疫筛选出来的，被发现是一种肿瘤特异性蛋白。因此，与 OCIAD1 一样，OCIAD2 预计在卵巢肿瘤中表现出高免疫反应性。在这项研究中，我们检查了 117 例卵巢黏液性肿瘤中 OCIAD2 的表达模式，并证实它在交界性肿瘤和癌（51/74 例，69%）中的表达高于腺瘤（6/43 例，14%）。OCIAD2 在交界性肿瘤和癌中的免疫反应性比 OCIAD1（腺瘤，21/43 例，49%）更具特异性，比 CEA（交界性肿瘤和癌，35/74 例，47%）更敏感。与 OCIAD1 一样，OCIAD2 是一种与癌症相关的蛋白质，其表达水平在恶性进展过程中增加，被认为是评估卵巢黏液性肿瘤恶性程度的非常有用的标志物。
